Locations:
Search IconSearch

Tag: diabetic macular edema (DME)

Diabetic retinopathy

Anti-VEGF in the Real World: Who Is at Risk of Vision Loss After Lapse in Treatment?

Study identifies factors that may predict vision outcomes in diabetic macular edema

23-EYE-3521610 CQD-Time to resolution of DME-Talcott-650×450
February 8, 2023/Diabetes & Endocrinology

Diabetic Macular Edema Can Take 1-2 Years to Resolve in Patients Despite Aggressive Treatment

Greater central subfield thickness and better visual acuity at baseline are associated with longer time to resolution

Eye exam

Even Brief Delays in Intravitreal Injection Can Cause Vision Loss

Patients with diabetic eye disease are most affected

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

20-EYE-1961371-CQD-AI-radiomics-in-diabetic-eye-disease-Hero

Retinal Leakage Pattern and Vascular Tortuosity May Predict Durability of Anti-VEGF Therapy

Radiomics analysis suggests underlying subvisual features may encode information related to tolerance of interval extension in retinal vascular disease

20-EYE-1964900-Lapse-in-AMD-and-DME-treatment-Hero

Consequences of Lapse in Anti-VEGF Therapy During the COVID-19 Pandemic

Studies evaluate patients who missed treatments for diabetic macular edema and neovascular age-related macular degeneration

18-EYE-4207-DRIL-CQD-Feat

Predicting Visual Acuity Response to Anti-VEGF Therapy in Macular Edema Secondary to Retinal Vein Occlusion

Is disorganization of retinal inner layers (DRIL) a useful prognostic indicator?

Diabetic retinopathy

Advancing Insights into Diabetic Eye Disease

Despite significant progress, questions remain

BackPage 1 of 1Next

Advertisement

Ad